tiprankstipranks
Philip Morris (NYSE:PM) Rises on Solid Q1 Results
Market News

Philip Morris (NYSE:PM) Rises on Solid Q1 Results

Story Highlights

Adjusted earnings per share came in at $1.50, which beat analysts’ consensus estimate of $1.41 per share.

Shares of tobacco company Philip Morris (NYSE:PM) are up today after it reported earnings for its first quarter of Fiscal Year 2024. Adjusted earnings per share came in at $1.50, which beat analysts’ consensus estimate of $1.41 per share.

Don't Miss our Black Friday Offers:

Furthermore, sales increased by 9.7% year-over-year, with revenue hitting $8.8 billion. This was $350 million above expectations.

Looking forward, management now expects adjusted EPS for FY 2024 to be in the range of $6.19 to $6.31. For reference, analysts were expecting an EPS figure of $6.33. In addition, organic revenue growth is expected to be between 7% and 8.5% year-over-year versus estimates of 5.28%.

Is PM Stock a Buy or Sell?

Turning to Wall Street, analysts have a Moderate Buy consensus rating on PM stock based on seven Buys, three Holds, and one Sell assigned in the past three months, as indicated by the graphic below. After a 3% increase in its share price over the past year, the average PM price target of $102.50 per share implies 6.74% upside potential. However, it’s worth noting that estimates will likely change following today’s earnings report.

PM also pays out a quarterly dividend, which yields 5.82%. This is above its sector average of 2.125%.

Is PM the Right Stock to Buy for Passive Income? 

Before you hurry to invest in PM, think about the following: 

TipRanks’ team has built a Smart Dividend Stock Portfolio for investors, and Philip Morris is included. Our portfolio highlights companies that have been hand-picked for their potential to deliver significant passive income for years to come. 
See Smart Dividend Portfolio >>

Related Articles
TheFlyLone Pine takes new positions in Salesforce and Starbucks, exits Mastercard
TheFlyLone Pine buys UnitedHealth, exits Workday in Q3
TheFlyFDA reauthorizes Swedish Match’s General snus as Modified Risk Tobacco Product
Go Ad-Free with Our App